{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T23:56:50Z","timestamp":1783382210484,"version":"3.54.6"},"reference-count":107,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jcyt.2026.102776","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T07:50:11Z","timestamp":1773215411000},"page":"102776","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Overcoming five main challenges to targeting hematologic malignancies"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0482-8580","authenticated-orcid":false,"given":"Megha","family":"Thakkar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick J.","family":"Hanley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexey","family":"Bersenev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0881-3167","authenticated-orcid":false,"given":"David H.","family":"Steffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcyt.2026.102776_bib0001","doi-asserted-by":"crossref","first-page":"16015","DOI":"10.1038\/mto.2016.15","article-title":"Clinical manufacturing of CAR T cells: foundation of a promising therapy","volume":"3","author":"Wang","year":"2016","journal-title":"Mol Ther Oncolytics"},{"key":"10.1016\/j.jcyt.2026.102776_bib0002","article-title":"CAR-T cell therapy in hematological malignancies: current opportunities and challenges","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcyt.2026.102776_bib0003","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2023.2210046","article-title":"Kymriah\u00ae (tisagenlecleucel)\u2014an overview of the clinical development journey of the first approved CAR-T therapy","volume":"19","author":"Awasthi","year":"2023","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.jcyt.2026.102776_bib0004","doi-asserted-by":"crossref","first-page":"e138","DOI":"10.1634\/theoncologist.2019-0395","article-title":"Axicabtagene ciloleucel, an anti-CD19 chimeric antigen receptor T-cell therapy for relapsed or refractory large B-cell lymphoma: practical implications for the community oncologist","volume":"25","author":"Jacobson","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.jcyt.2026.102776_bib0005","unstructured":"Squibb BM. U.S. FDA approves Bristol Myers Squibb\u2019s Breyanzi \u00ae as the first and only CAR T cell therapy for adults with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) 2024, Bristol Myers Squibb. [accessed 05.8.25]https:\/\/news.bms.com\/news\/details\/2024\/U.S.-FDA-Approves-Bristol-Myers-Squibbs-Breyanzi\u2013as-the-First-and-Only-CAR-T-Cell-Therapy-for-Adults-with-Relapsed-or-Refractory-Chronic-Lymphocytic-Leukemia-CLL-or-Small-Lymphocytic-Lymphoma-SLL\/default.aspx."},{"key":"10.1016\/j.jcyt.2026.102776_bib0006","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1188049","article-title":"From bench to bedside: the history and progress of CAR T cell therapy","volume":"14","author":"Mitra","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcyt.2026.102776_bib0007","doi-asserted-by":"crossref","first-page":"93","DOI":"10.46989\/001c.124277","article-title":"Overview of approved CAR-T products and utility in clinical practice","volume":"6","author":"Bhaskar","year":"2024","journal-title":"Clin Hematol Int"},{"key":"10.1016\/j.jcyt.2026.102776_bib0008","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/nrd.2017.266","article-title":"The market for chimeric antigen receptor T cell therapies","volume":"17","author":"Yip","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jcyt.2026.102776_bib0009","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2406526","article-title":"Obecabtagene autoleucel in adults with B-cell acute lymphoblastic leukemia","volume":"391","author":"Roddie","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2026.102776_bib0010","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jcyt.2022.10.002","article-title":"Emerging frontiers in immuno- and gene therapy for cancer","volume":"25","author":"Gustafson","year":"2023","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2026.102776_bib0011","first-page":"163","article-title":"Barriers to chimeric antigen receptor T-Cell (CAR-T) therapies in clinical practice","volume":"36","author":"Gajra","year":"2022","journal-title":"Pharmaceut Med"},{"key":"10.1016\/j.jcyt.2026.102776_bib0012","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.3389\/fimmu.2019.02664","article-title":"Mechanisms of relapse after CD19 CAR T-cell therapy for acute lymphoblastic leukemia and its prevention and treatment strategies","volume":"10","author":"Xu","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcyt.2026.102776_bib0013","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/ejh.14076","article-title":"CAR-T cell therapy in hematological malignancies: where are we now and where are we heading for?","volume":"112","author":"Khan","year":"2024","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jcyt.2026.102776_bib0014","series-title":"The EBMT\/EHA CAR-T cell handbook","first-page":"141","article-title":"Management of immune effector cell-associated neurotoxicity syndrome (ICANS)","author":"Rees","year":"2022"},{"key":"10.1016\/j.jcyt.2026.102776_bib0015","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1182\/blood.2023021860","article-title":"BCMA-CAR T-cell treatment\u2013associated parkinsonism","volume":"142","author":"Gust","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2026.102776_bib0016","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/s41571-020-00456-y","article-title":"Beyond the storm\u2014subacute toxicities and late effects in children receiving CAR T cells","volume":"18","author":"Shalabi","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jcyt.2026.102776_bib0017","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa2301665","article-title":"Survival with Axicabtagene ciloleucel in large B-cell lymphoma","volume":"389","author":"Westin","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2026.102776_bib0018","series-title":"Cell Therapy Breyanzi\u00ae (lisocabtagene maraleucel) approved for second-line relapsed or refractory diffuse large B-cell lymphoma","author":"CAR","year":"2023"},{"key":"10.1016\/j.jcyt.2026.102776_bib0019","article-title":"Long-term safety and efficacy of CART-20 cells in patients with refractory or relapsed B-cell non-Hodgkin lymphoma: 5-years follow-up results of the phase I and IIa trials","volume":"2","author":"Zhang","year":"2017","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.jcyt.2026.102776_bib0020","doi-asserted-by":"crossref","first-page":"5827","DOI":"10.1002\/cam4.3259","article-title":"Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma","volume":"9","author":"Sang","year":"2020","journal-title":"Cancer Med"},{"key":"10.1016\/j.jcyt.2026.102776_bib0021","doi-asserted-by":"crossref","first-page":"4023","DOI":"10.2147\/OTT.S312904","article-title":"Anti-CD22 CAR-T cell therapy as a salvage treatment in B cell malignancies refractory or relapsed after anti-CD19 CAR-T therapy","volume":"14","author":"Zhu","year":"2021","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.jcyt.2026.102776_bib0022","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1038\/s41375-019-0488-7","article-title":"CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia","volume":"33","author":"Pan","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.jcyt.2026.102776_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.107731","article-title":"Chimeric antigen receptor T cells targeting CD7 in a child with high-risk T-cell acute lymphoblastic leukemia","volume":"96","author":"Xie","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.jcyt.2026.102776_bib0024","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1158\/1078-0432.CCR-20-1271","article-title":"Eradication of T-ALL cells by CD7-targeted universal CAR-T cells and initial test of ruxolitinib-based CRS management","volume":"27","author":"Li","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jcyt.2026.102776_bib0025","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1200\/JCO.21.00389","article-title":"Donor-derived CD7 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia: first-in-human, phase I trial","volume":"39","author":"Pan","year":"2021","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.jcyt.2026.102776_bib0026","doi-asserted-by":"crossref","first-page":"4602","DOI":"10.1182\/blood-2022-165819","article-title":"Efficacy and safety of donor-derived CD7 CAR T cells for r\/r T-cell acute lymphoblastic leukemia\/lymphoma: interim analysis from a phase 2 trial","volume":"140","author":"JP","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2026.102776_bib0027","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s12015-019-09937-9","article-title":"Characterization of an anti- CD5 directed CAR T-cell against T-cell malignancies","volume":"16","author":"Wada","year":"2020","journal-title":"Stem Cell Rev Rep"},{"key":"10.1016\/j.jcyt.2026.102776_bib0028","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1007\/s12015-020-10092-9","article-title":"Treatment of aggressive T cell lymphoblastic lymphoma\/leukemia using anti-CD5 CAR T cells","volume":"17","author":"Feng","year":"2021","journal-title":"Stem Cell Rev Rep"},{"key":"10.1016\/j.jcyt.2026.102776_bib0029","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/leu.2015.311","article-title":"Preclinical targeting of human T-cell malignancies using CD4-specific chimeric antigen receptor (CAR)-engineered T cells","volume":"30","author":"Pinz","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.jcyt.2026.102776_bib0030","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1182\/blood.2023022204","article-title":"Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed\/refractory mature T-cell lymphomas","volume":"143","author":"Hill","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2026.102776_bib0031","series-title":"first-in-class CD5 CAR-T cell therapy for T-Cell lymphomaBioSpace","article-title":"BioSpace March biosciences announces first patient dosed in phase 2 clinical trial of MB-105","year":"2025"},{"key":"10.1016\/j.jcyt.2026.102776_bib0032","author":"Biotherapeutics"},{"key":"10.1016\/j.jcyt.2026.102776_bib0034","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1158\/1078-0432.CCR-16-1365","article-title":"Autologous T cells expressing CD30 chimeric antigen receptors for relapsed or refractory Hodgkin lymphoma: an open-label phase I trial","volume":"23","author":"Wang","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jcyt.2026.102776_bib0035","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1200\/JCO.20.01342","article-title":"Anti-CD30 CAR-T cell therapy in relapsed and refractory Hodgkin lymphoma","volume":"38","author":"Ramos","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jcyt.2026.102776_bib0036","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41408-020-0274-9","article-title":"Anti-CD30 chimeric antigen receptor T cell therapy for relapsed\/refractory CD30(+) lymphoma patients","volume":"10","author":"Wang","year":"2020","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.jcyt.2026.102776_bib0037","doi-asserted-by":"crossref","first-page":"E358","DOI":"10.1016\/S2352-3026(24)00064-4","article-title":"Anti-CD30 CAR T cells as consolidation after autologous haematopoietic stem-cell transplantation in patients with high-risk CD30+ lymphoma: a phase 1 study","volume":"11","author":"Natalie","year":"2024","journal-title":"Lancet Hematol"},{"issue":"Supplement 1","key":"10.1016\/j.jcyt.2026.102776_bib0038","doi-asserted-by":"crossref","first-page":"4584","DOI":"10.1182\/blood-2022-170201","article-title":"Safety and anti-leukemic activity of CD123-CAR T cells in pediatric patients with AML: preliminary results from a phase 1 trial","volume":"140","author":"Naik","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2026.102776_bib0039","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000845","article-title":"41BB-based and CD28-based CD123-redirected T-cells ablate human normal hematopoiesis in vivo","volume":"8","author":"Baroni","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jcyt.2026.102776_bib0040","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.omto.2020.04.009","article-title":"Rapidly switchable universal CAR-T cells for treatment of CD123-positive leukemia","volume":"17","author":"Loff","year":"2020","journal-title":"Mol Ther Oncolytics"},{"key":"10.1016\/j.jcyt.2026.102776_bib0041","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.1182\/blood.2020009759","article-title":"Proof of concept for a rapidly switchable universal CAR-T platform with UniCAR-T-CD123 in relapsed\/refractory AML","volume":"137","author":"Wermke","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2026.102776_bib0042","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.1038\/s41375-021-01232-2","article-title":"Autologous CD33-CAR-T cells for treatment of relapsed\/refractory acute myelogenous leukemia","volume":"35","author":"Tambaro","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.jcyt.2026.102776_bib0043","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13045-021-01092-4","article-title":"CD38-directed CAR-T cell therapy: a novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation","volume":"14","author":"Cui","year":"2021","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.jcyt.2026.102776_bib0044","doi-asserted-by":"crossref","first-page":"8443","DOI":"10.1158\/0008-5472.CAN-04-1659","article-title":"C-type lectin-like molecule-1: a novel myeloid cell surface marker associated with acute myeloid leukemia","volume":"64","author":"Bakker","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.jcyt.2026.102776_bib0045","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13045-017-0553-5","article-title":"CAR-T cells targeting CLL-1 as an approach to treat acute myeloid leukemia","volume":"11","author":"Wang","year":"2018","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.jcyt.2026.102776_bib0046","doi-asserted-by":"crossref","first-page":"208","DOI":"10.3892\/mmr.2021.11847","article-title":"Cytotoxic effect of CLL\u20111 CAR\u2011T cell immunotherapy with PD\u20111 silencing on relapsed\/refractory acute myeloid leukemia","volume":"23","author":"Lin","year":"2021","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.jcyt.2026.102776_bib0047","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1182\/blood.2020008221","article-title":"CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity","volume":"138","author":"Sauer","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2026.102776_bib0048","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1038\/s41591-020-0910-8","article-title":"Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents","volume":"26","author":"Riether","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.jcyt.2026.102776_bib0049","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1016\/j.ymthe.2018.08.001","article-title":"A novel anti-LILRB4 CAR-T cell for the treatment of monocytic AML","volume":"26","author":"John","year":"2018","journal-title":"Mol Ther"},{"key":"10.1016\/j.jcyt.2026.102776_bib0050","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1182\/blood.2020009192","article-title":"Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia","volume":"138","author":"Jetani","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2026.102776_bib0051","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1016\/j.ymthe.2020.06.022","article-title":"Allogeneic FLT3 CAR T cells with an off-switch exhibit potent activity against AML and can be depleted to expedite bone marrow recovery","volume":"28","author":"Sommer","year":"2020","journal-title":"Mol Ther"},{"issue":"Supplement 1","key":"10.1016\/j.jcyt.2026.102776_bib0052","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2021-151196","article-title":"Anti-FLT3 CAR T cells in acute myeloid leukemia","volume":"138","author":"Sara","year":"2021","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.jcyt.2026.102776_bib0053","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.3390\/biomedicines10102441","article-title":"Recent advances in the development of anti-FLT3 CAR T-cell therapies for treatment of AML","volume":"10","author":"Pedersen","year":"2022","journal-title":"Biomedicines"},{"issue":"Supplement 1","key":"10.1016\/j.jcyt.2026.102776_bib0054","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1182\/blood-2023-180387","article-title":"A phase I clinical trial of CLL-1 CAR-T cells for the treatment of relapsed\/refractory acute myeloid leukemia in adults","volume":"142","author":"Zhang","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2026.102776_bib0055","series-title":"Blood","article-title":"Phase I clinical trial of autologous CLL1 CAR-T therapy for pediatric patients with relapsed and refractory acute myeloid leukemia","author":"Bu","year":"2020"},{"key":"10.1016\/j.jcyt.2026.102776_bib0056","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1111\/bjh.18971","article-title":"FLT3-directed UniCAR T-cell therapy of acute myeloid leukaemia","volume":"202","author":"Peschke","year":"2023","journal-title":"Br J Haematol"},{"issue":"Supplement 1","key":"10.1016\/j.jcyt.2026.102776_bib0057","doi-asserted-by":"crossref","first-page":"10233","DOI":"10.1182\/blood-2022-158452","article-title":"The race is on: BiTE vs CART as FLT3-directed immunotherapies in AML","volume":"140","author":"Rohrbacher","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2026.102776_bib0058","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide- refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2026.102776_bib0059","unstructured":"Johnson & Johnson. CARVYKTI\u00ae is the first and only BCMA-targeted treatment approved by the U.S. FDA for patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy [Press release]. 2024. [accessed 05.8.25].https:\/\/www.jnj.com\/media-center\/press-releases\/carvykti-is-the-first-and-only-bcma-targeted-treatment-approved-by-the-u-s-fda-for-patients-with-relapsed-or-refractory-multiple-myeloma-who-have-received-at-least-one-prior-line-of-therapy"},{"issue":"Supplement 1","key":"10.1016\/j.jcyt.2026.102776_bib0060","doi-asserted-by":"crossref","first-page":"3385","DOI":"10.1182\/blood-2024-199913","article-title":"BCMA CAR-T therapy as first- line consolidation treatment in transplant-ineligible patients with newly-diagnosed multiple myeloma: an open label, single-arm, phase 2 study (CAREMM-001)","volume":"144","author":"Yan","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2026.102776_bib0061","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1016\/j.ymthe.2025.03.061","article-title":"How to democratize cell and gene therapy: a global approach","volume":"33","author":"Rayne","year":"2025","journal-title":"Mol Ther"},{"key":"10.1016\/j.jcyt.2026.102776_bib0062","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jcyt.2021.09.009","article-title":"ISCT survey on hospital practices to support externally manufactured investigational cell-gene therapy products","volume":"24","author":"Bersenev","year":"2022","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2026.102776_bib0063","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s12254-022-00859-w","article-title":"Barriers to patient access of CAR T cell therapies in Austria","volume":"16","author":"Hopfinger","year":"2023","journal-title":"memo"},{"key":"10.1016\/j.jcyt.2026.102776_bib0064","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2023.101136","article-title":"Access to CAR T-cell therapy: focus on diversity, equity and inclusion","volume":"63","author":"Odstrcil","year":"2024","journal-title":"Blood Rev"},{"key":"10.1016\/j.jcyt.2026.102776_bib0065","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1182\/blood.2023020703","article-title":"Mitigating inequity: ethically prioritizing patients for CAR T-cell therapy","volume":"142","author":"Bell","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2026.102776_bib0066","doi-asserted-by":"crossref","first-page":"e786","DOI":"10.1016\/S2352-3026(22)00226-5","article-title":"Access to and affordability of CAR T-cell therapy in multiple myeloma: an EBMT position paper","volume":"9","author":"Gagelmann","year":"2022","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jcyt.2026.102776_bib0067","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.jtct.2022.04.008","article-title":"Socioeconomic and racial disparity in chimeric antigen receptor T cell therapy access","volume":"28","author":"Ahmed","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jcyt.2026.102776_bib0068","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1182\/hematology.2023000518","article-title":"Barriers to accessing cellular therapy for patients receiving care in community practices","volume":"2023","author":"Nze","year":"2023","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.jcyt.2026.102776_bib0069","doi-asserted-by":"crossref","DOI":"10.3389\/frtra.2023.1238535","article-title":"Promises and challenges of a decentralized CAR T-cell manufacturing model","volume":"2","author":"Shah","year":"2023","journal-title":"Front Transplant"},{"key":"10.1016\/j.jcyt.2026.102776_bib0070","article-title":"Accelerating CAR T cell manufacturing with an automated next-day process","volume":"73","author":"Ahmadi","year":"2025","journal-title":"Curr Res Transl Med"},{"key":"10.1016\/j.jcyt.2026.102776_bib0071","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41408-022-00694-6","article-title":"Next-day manufacture of a novel anti- CD19 CAR-T therapy for B-cell acute lymphoblastic leukemia: first-in-human clinical study","volume":"12","author":"Yang","year":"2022","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.jcyt.2026.102776_bib0072","unstructured":"Gilead Sciences Inc. Kite receives U.S. FDA approval of manufacturing process change resulting in reduced median turnaround time for Yescarta\u00ae CAR T-cell therapy [Press release] 2024.https:\/\/www.kitepharma.com\/news\/press-releases\/2024\/1\/kite-receives-us-fda-approval-of-manufacturing-process-change-resulting-in-reduced-median-turnaround-time-for-yescarta-car-tcell-therapy."},{"key":"10.1016\/j.jcyt.2026.102776_bib0073","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jcyt.2021.09.010","article-title":"Delivering externally manufactured cell and gene therapy products to patients: perspectives from the academic center experience","volume":"24","author":"Hanley","year":"2022","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2026.102776_bib0074","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/cgt.2014.71","article-title":"Manufacturing genetically modified T cells for clinical trials","volume":"22","author":"Gee","year":"2015","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.jcyt.2026.102776_bib0075","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/j.jcyt.2024.06.008","article-title":"Environmental monitoring of current good manufacturing practices cleanroom facilities for manufacturing of cellular therapy products in an academic hospital setting","volume":"26","author":"Tanna","year":"2024","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2026.102776_bib0076","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1158\/2643-3230.BCD-21-0084","article-title":"Scalable manufacturing of CAR T cells for cancer immunotherapy","volume":"2","author":"Abou-el-Enein","year":"2021","journal-title":"Blood Cancer Discov"},{"key":"10.1016\/j.jcyt.2026.102776_bib0077","doi-asserted-by":"crossref","first-page":"7200","DOI":"10.1038\/s41467-021-27312-6","article-title":"Multiple site place-of-care manufactured anti-CD19 CAR-T cells induce high remission rates in B-cell malignancy patients","volume":"12","author":"Maschan","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.jcyt.2026.102776_bib0078","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1038\/s41587-023-01981-8","article-title":"Expanding access to CAR T cell therapies through local manufacturing","volume":"41","author":"Elsallab","year":"2023","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jcyt.2026.102776_bib0079","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/nbt.3525","article-title":"Quality cell therapy manufacturing by design","volume":"34","author":"Lipsitz","year":"2016","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jcyt.2026.102776_bib0080","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jcyt.2020.09.013","article-title":"Processing laboratory considerations for multi-center cellular therapy clinical trials: a report from the Consortium for Pediatric Cellular Immunotherapy","volume":"23","author":"Lindgren","year":"2021","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2026.102776_bib0081","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1038\/s41591-024-03035-1","article-title":"Enhancing pediatric access to cell and gene therapies","volume":"30","author":"Mackall","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.jcyt.2026.102776_bib0082","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.jtct.2024.05.010","article-title":"ACT to sustain: adoptive cell therapy to sustain access to non-commercialized genetically modified cell therapies","volume":"30","author":"Gardner","year":"2024","journal-title":"Transplant Cell Ther."},{"key":"10.1016\/j.jcyt.2026.102776_bib0083","first-page":"365","article-title":"The cost of biotech innovation: exploring research and development costs of cell and gene therapies","volume":"37","author":"Sabatini","year":"2023","journal-title":"Pharmaceut Med"},{"key":"10.1016\/j.jcyt.2026.102776_bib0084","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","article-title":"Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults","volume":"129","author":"Gardner","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2026.102776_bib0085","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1056\/NEJMoa2027675","article-title":"Autologous ex vivo lentiviral gene therapy for adenosine deaminase deficiency","volume":"384","author":"Kohn","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2026.102776_bib0086","series-title":"Gene therapy for ADA-SCID shows promise","year":"2022"},{"key":"10.1016\/j.jcyt.2026.102776_bib0087","doi-asserted-by":"crossref","first-page":"4320","DOI":"10.1182\/bloodadvances.2024013239","article-title":"Outpatient administration of CAR T-cell therapies using a strategy of no remote monitoring and early CRS intervention","volume":"8","author":"Furqan","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.jcyt.2026.102776_bib0088","doi-asserted-by":"crossref","first-page":"6114","DOI":"10.1182\/bloodadvances.2024013254","article-title":"OUTREACH: phase 2 study of Lisocabtagene maraleucel as outpatient or inpatient treatment at community sites for R\/R LBCL","volume":"8","author":"Linhares","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.jcyt.2026.102776_bib0089","series-title":"Autolus secures FDA approval for CAR-T cell therapy use in ALL","author":"Philpott","year":"2024"},{"key":"10.1016\/j.jcyt.2026.102776_bib0091","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/cgt.2014.78","article-title":"Towards a commercial process for the manufacture of genetically modified T cells for therapy","volume":"22","author":"Kaiser","year":"2015","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.jcyt.2026.102776_bib0092","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/j.jcyt.2023.08.007","article-title":"A simulation-based comparison of centralized and point-of-care supply chain strategies for autologous cell therapy","volume":"25","author":"Wang","year":"2023","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2026.102776_bib0093","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1005457","article-title":"Practical aspects of chimeric antigen receptor T-cell administration: from commercial to point-of-care manufacturing","volume":"13","author":"Martinez-Cibrian","year":"2022","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.jcyt.2026.102776_bib0094","article-title":"Point-of-care manufacturing of anti-CD19 CAR-T cells using a closed production platform: experiences of an academic in Thailand","volume":"32","author":"Luanpitpong","year":"2024","journal-title":"Mol Ther Oncol"},{"key":"10.1016\/j.jcyt.2026.102776_bib0095","doi-asserted-by":"crossref","first-page":"4838","DOI":"10.1182\/blood-2023-185507","article-title":"High efficacy and excellent safety profile of Actalycabtagene autoleucel, a humanized CD19 CAR-T product in r\/r B-cell malignancies: a phase II pivotal trial","volume":"142","author":"Jain","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2026.102776_bib0096","series-title":"India\u2019s first homegrown CAR T-cell therapy has roots in NCI collaboration","author":"Wang","year":"2024"},{"key":"10.1016\/j.jcyt.2026.102776_bib0097","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/d41586-024-00809-y","article-title":"Cutting-edge CAR-T cancer therapy is now made in India\u2014at one-tenth the cost","volume":"627","author":"Mallapaty","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.jcyt.2026.102776_bib0098","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.ymthe.2020.09.027","article-title":"CART19-BE-01: a multicenter trial of ARI-0001 cell therapy in patients with CD19(+) relapsed\/refractory malignancies","volume":"29","author":"Ort\u00edz-Maldonado","year":"2021","journal-title":"Mol Ther"},{"issue":"12","key":"10.1016\/j.jcyt.2026.102776_bib0099","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003644","article-title":"Factors associated with the clinical outcome of patients with relapsed\/refractory CD19(+) acute lymphoblastic leukemia treated with ARI-0001 CART19-cell therapy","volume":"9","author":"Ortiz-Maldonado","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jcyt.2026.102776_bib0100","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1182\/blood-2023-172736","article-title":"Seven-day vein-to-vein point-of-care manufactured CD19 CAR T cells (GLPG5101) in relapsed\/refractory NHL: results from the phase 1 atalanta-1 trial","volume":"114","author":"Kersten","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2026.102776_bib0101","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.jcyt.2024.03.009","article-title":"Accelerating the development of genetically engineered cellular therapies: a framework for extrapolating data across related products","volume":"26","author":"Stewart","year":"2024","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2026.102776_bib0102","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1158\/0008-5472.CAN-14-3321","article-title":"Multiplex genome-edited T-cell manufacturing platform for \u201coff-the-shelf\u201d adoptive T-cell immunotherapies","volume":"75","author":"Poirot","year":"2015","journal-title":"Cancer Res"},{"issue":"Supplement_1","key":"10.1016\/j.jcyt.2026.102776_bib0103","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1182\/blood-2019-121751","article-title":"A feasibility and safety study of a new CD19-directed fast CAR-T therapy for refractory and relapsed B cell acute lymphoblastic leukemia","volume":"134","author":"Yang","year":"2019","journal-title":"Blood"},{"issue":"Supplement_1","key":"10.1016\/j.jcyt.2026.102776_bib0104","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1182\/blood-2019-128006","article-title":"CD19-directed fast CART therapy for relapsed\/refractory acute lymphoblastic leukemia: from bench to bedside","volume":"134","author":"Zhang","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2026.102776_bib0105","first-page":"25","article-title":"Clinical results of a multicenter study of the first-in-human dual BCMA and CD19 targeted novel platform fast CAR-T cell therapy for patients with relapsed\/refractory multiple myeloma","volume":"136","author":"Jiang","year":"2020","journal-title":"Blood"},{"issue":"16_suppl","key":"10.1016\/j.jcyt.2026.102776_bib0106","doi-asserted-by":"crossref","first-page":"8005","DOI":"10.1200\/JCO.2023.41.16_suppl.8005","article-title":"Updated results of a phase I, open-label study of BCMA\/CD19 dual-targeting fast CAR-T GC012F for patients with relapsed\/refractory multiple myeloma (RRMM)","volume":"41","author":"Du","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jcyt.2026.102776_bib0107","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1182\/blood-2023-174841","article-title":"Updated results of a phase I open-label single-arm study of dual targeting BCMA and CD19 fastcar-T cells (GC012F) as first-line therapy for transplant-eligible newly diagnosed high-risk multiple myeloma","volume":"142","author":"Du","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2026.102776_bib0108","doi-asserted-by":"crossref","first-page":"6847","DOI":"10.1182\/blood-2023-185476","article-title":"CD19\/BCMA dual-targeting fastcar- T GC012F for patients with relapsed\/refractory B-cell non-Hodgkin\u2019s lymphoma: an update","volume":"142","author":"Chen","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2026.102776_bib0109","first-page":"2060","article-title":"Shortening the time to manufacture CAR+ T cells with sleeping beauty system supports T-cell engraftment and anti- tumor effects in patients with refractory CD19+ tumors","volume":"130","author":"Kebriaei","year":"2017","journal-title":"Blood"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324926007371?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324926007371?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T11:26:28Z","timestamp":1783337188000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324926007371"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":107,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S1465324926007371"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2026.102776","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Overcoming five main challenges to targeting hematologic malignancies","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2026.102776","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society for Cellular Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102776"}}